|
The newly discovered tools of proteomics research offer a powerful approach to identify specific antigens as targets for the development of immunotherapeutics. The limitation of this approach has been the difficulty in developing a method for the separation of complex mixtures of proteins that can yield specific differences between populations of cells or tissues. To define surface expressed proteins that are preferentially expressed on tumor cells, MacroGenics leverages its proprietary expertise in membrane purification technology and peptide labeling using isotope coded affinity tag (ICAT) and peptide identification using tandem mass spectrometry technology.
The technology is widely applicable to a variety of tissue samples, body fluids, cell lines or other pathological material. When combined with genomic approaches, the proteomic information offers a powerful integration for identification of target molecules.
|
